

2017

Recent advances in understanding, diagnosing, and treating ovarian cancer [version 1; referees: 3 approved]

Kathryn Mills

Washington University School of Medicine in St. Louis

Katherine Fuh

Washington University School of Medicine in St. Louis

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Mills, Kathryn and Fuh, Katherine, "Recent advances in understanding, diagnosing, and treating ovarian cancer [version 1; referees: 3 approved]." *F1000Research*.6, 84. (2017).

http://digitalcommons.wustl.edu/open_access_pubs/5622

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.



REVIEW

Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer [version 1; referees: 3 approved]

Kathryn Mills, Katherine Fuh

Washington University School of Medicine, St. Louis, MO, USA

v1 **First published:** 27 Jan 2017, 6(F1000 Faculty Rev):84 (doi: 10.12688/f1000research.9977.1)
Latest published: 27 Jan 2017, 6(F1000 Faculty Rev):84 (doi: 10.12688/f1000research.9977.1)

Abstract

Ovarian cancer, a term that encompasses ovarian, fallopian, and peritoneal cancers, is the leading cause of gynecologic cancer mortality. To improve patient outcomes, the field is currently focused on defining the mechanisms of cancer formation and spread, early diagnosis and prevention, and developing novel therapeutic options. This review summarizes recent advances in these areas.

Open Peer Review

Referee Status:

	Invited Referees		
	1	2	3
version 1 published 27 Jan 2017			

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **Steven Narod**, Women's College Hospital
Canada, University of Toronto Canada
- 2 **Jonathan Berek**, Stanford University
School of Medicine USA
- 3 **Ronny Drapkin**, University of
Pennsylvania, Perelman School of
Medicine USA

Discuss this article

Comments (0)

Corresponding author: Katherine Fuh (kfuh@wudosis.wustl.edu)

How to cite this article: Mills K and Fuh K. **Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer [version 1; referees: 3 approved]** *F1000Research* 2017, 6(F1000 Faculty Rev):84 (doi: [10.12688/f1000research.9977.1](https://doi.org/10.12688/f1000research.9977.1))

Copyright: © 2017 Mills K and Fuh K. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Competing interests: The authors declare that they have no competing interests.

First published: 27 Jan 2017, 6(F1000 Faculty Rev):84 (doi: [10.12688/f1000research.9977.1](https://doi.org/10.12688/f1000research.9977.1))

Introduction

Ovarian cancer was first identified in 1959 by Dr Martin Swerdlow, who described a malignant pelvic mass that surrounded the left fallopian tube but did not involve the mucosal epithelium. This tumor was thought to develop from tissue with an origin similar to that of the ovary, such as the pelvic peritoneum, fallopian tubes, or uterus¹. Since then, cancers of these tissues have been collectively referred to as Müllerian adenocarcinomas to reflect the fact that we often do not know exactly which organ these tumors originate from. However, for simplicity, we will refer to these tumors by their more common name, ovarian cancers. Ovarian cancer is the most lethal gynecologic malignancy and is the fifth most common cause of cancer death in women^{2,3}.

The majority of women with ovarian cancer are diagnosed with advanced-stage disease; only 15% of all cases are diagnosed with local disease^{2,3}. Since the 1970s, the five-year survival for all stages has improved from 30% to 46%³ as a result of taxane and platinum chemotherapies, intraperitoneal (IP) administration of chemotherapy, and risk-reduction surgeries. However, five-year survival for advanced disease, such as stage IIIc, is a mere 39%. Risk factors for ovarian cancer include family history, nulliparity, lack of breast feeding, and infertility⁴. In addition, between 5% and 15% of all women with ovarian cancer have inherited mutations in DNA repair genes such as *BRCA1*, *BRCA2*, and genes associated with Lynch syndrome⁴⁻⁷. *BRCA1*, *BRCA2*, and Lynch mutations increase the lifetime risks of ovarian cancer by as much as 60-, 30-, and 13-fold, respectively^{5,8}. Currently, the field is focused on defining the mechanisms of cancer formation and spread, early diagnosis and prevention, and developing novel therapeutic options. This review highlights some of the newest findings in these areas.

Mechanisms of ovarian cancer formation and spread

Tumor types

The majority of ovarian cancers are of epithelial histology, and high-grade serous carcinomas (HGSCs) are the most common, but there are other epithelial histologic subtypes, such as clear cell, endometrioid, and mucinous⁴. These can be divided into two major subtypes: type I and type II. Type I cancers (clear cell, endometrioid, and low-grade serous) grow slowly and seem to develop in a step-wise process. For example, low-grade serous tumors arise from benign serous cystadenoma or Müllerian inclusion cysts that accumulate mutations in pathways such as *KRAS* and *BRAF*⁹. Likewise, clear cell and endometrioid carcinomas may originate from endometriosis as shown by the finding that the prevalence of self-reported endometriosis was higher in women with clear cell (20%) and endometrioid (14%) cancers than in those with low-grade serous (9.2%) or mucinous (6%) cancers¹⁰. Type II tumors are characterized by high-grade, rapidly progressive disease, and most commonly a serous histology^{11,12}.

Origin of disease

Although ovarian cancers were traditionally thought to originate from the surface epithelium of the ovary, there is strong evidence that a portion (50–60%) of high-grade serous ovarian tumors arise from the fallopian tube, and many pathologists have described

pre-invasive dysplastic lesions within the distal end of the fallopian tube. These serous tubal intraepithelial carcinoma (STIC) lesions^{11,13-16} often resemble high-grade serous cancer, confirming that ovarian serous cancer can originate in the fallopian tube. However, two recent studies indicate that STIC lesions sometimes represent a metastatic site rather than assumptive primary fallopian tube cancers^{17,18}. In one study, Eckert *et al.* implanted HGSC spheroids into the fallopian tube epithelium in mice and showed that this fallopian tube growth histologically mimicked STIC lesions¹⁷. In another study, McDaniel *et al.* performed targeted next-generation sequencing of an incidental STIC lesion and found that it matched the associated uterine endometrioid carcinoma, strongly indicating that the STIC lesion originated as a micrometastasis from the primary tumor¹⁸. Thus, although certain aspects regarding the origins of high-grade serous ovarian cancer are understood, unanswered questions continue to challenge the field.

Mutations and pathways

The Cancer Genome Atlas study characterized 316 primary HGSC specimens and detected *TP53* mutations in 100% of specimens and *BRCA1* and *BRCA2* mutations (both somatic and germline) in 20%^{19,20}. Most tumors were characterized by global genomic instability. More recent advances in DNA sequencing technology have identified additional mutations in ovarian cancer, including *BARD1*, *BRIP1*, *CHEK2*, *NBN*, *PALB2*, *RAD50* family, and *NFI*^{12,21-26}. Given that these genes are involved in DNA repair, women with ovarian cancer, as well as their family members, are at risk of developing other cancers and thus should be referred for genetic counseling and testing²⁷.

In ovarian cancer, as in other cancers, resistance to chemotherapy is common. To identify genes conferring chemoresistance, Patch *et al.* analyzed whole genome sequences of 92 patients with HGSC to characterize mutations from three groups of tumors: those that were sensitive to platinum, those that initially responded but then developed resistance, and those that did not respond at all²⁸. They found *TP53* mutations in all samples but found only a few, low-frequency, actionable genetic alterations amongst the chemoresistant patients. These included reversion of germline mutations in *BRCA1* and *BRCA2*, mutations in the pro-apoptotic genes *FOXO1* and *BCL2L11*, and increased expression of *ABCB1*, which encodes a cellular drug efflux pump. More work is clearly needed to uncover mechanisms of chemoresistance and strategies to overcome it.

Mechanisms of metastasis

Ovarian cancers are extremely prone to metastasize, particularly to the omentum. Two routes have been proposed to explain how ovarian cancer cells reach the omentum. First, they may travel through the bloodstream, as suggested by Sood *et al.*²⁹. These authors vascularly conjoined 15 pairs of mice, intraperitoneally injected tumor cells into “host” mice, and found that half of the conjoined “guest” mice developed omental or mesenteric metastases. Tumor cells also reached the guest mouse when the cancer cells were injected into host ovaries or vasculature. The authors further found that the metastatic cells significantly upregulated expression of epidermal growth factor receptor family genes, specifically *ErbB3*, and that

targeting *ErbB3* with small interfering RNA significantly inhibited omental tumor establishment and also the size and number of tumors²⁹. A second theory is that ovarian cancer cells metastasize by shedding into the peritoneal space and then attaching to nearby structures, such as the omentum. Support for this model comes from Lengyel *et al.*, who showed that omental adipocytes promote metastasis to the omentum by upregulating expression of fatty acid-binding protein 4 (*FABP4*)³⁰. *FABP4* was strongly expressed at the adipocyte–cancer cell interface, and mice lacking *FABP4* had a significantly lower tumor burden than wild-type mice. Future work will hopefully reveal whether the hematogenous or the shedding route predominates in different ovarian cancer types so that therapies can be developed to prevent it.

Tumor cells and the microenvironment

Mutations do not explain the full spectrum of tumor behaviors, which also depend on the tumor microenvironment, or stroma, a mixture of extracellular matrix, mesothelial cells, fibroblasts, endothelial cells, blood and lymph vessels, nerves, immune cells, and adipocytes^{31–33}. Two hallmarks of cancer that depend on the tumor microenvironment are (1) stromal invasion and metastasis and (2) angiogenesis. Because stromal components contribute to ovarian cancer metastasis, many investigators are developing *in vitro* methods to study interactions with the tumor cells and identify strategies to inhibit metastasis by targeting tumor/microenvironment interactions. These methods include three-dimensional matrices, cancer cell spheroids, and co-cultured mesothelium (the first layer of the omentum) with cancer cells³⁴. In studies with spheroids, Davidowitz *et al.* found that tumor cell spheroids that upregulated their expression of epithelial-to-mesenchymal transition transcription factors (in particular, *SNAIL1*, *TWIST1*, and *ZEB1*) were better able to clear the mesothelium (an essential step in metastasis) than cells that did not upregulate these factors³⁵. Additionally, receptor tyrosine kinases such as *AXL* and *DDR2* have been found to regulate tumor cell clearance of primary, patient-derived mesothelial cells^{36,37}. For angiogenesis, Sood *et al.* used a xenograft approach to model what happens when a patient stops taking an anti-angiogenic drug such as bevacizumab or pazopanib³⁸. They found that mice with higher circulating platelet levels had greater tumor weight and markers of proliferation and decreased levels of apoptosis. Furthermore, this group demonstrated that tumor infiltration of platelets after withdrawal of anti-angiogenic agents may contribute to rebound tumor growth. Incorporating the tumor microenvironment in future work will continue to lead to a better understanding of ovarian carcinogenesis and metastasis.

Translational mouse models

Understanding disease pathogenesis necessitates models that mimic patient tumor behavior and interaction with the microenvironment. One approach is to develop genetically engineered mouse models (GEMMs), in which a mouse's genome is modified to cause development of a murine disease that mimics human disease, although such models have not clearly resolved the question about the origin of ovarian tumors. Some authors have created conditional GEMMs that point to the ovary as the origin^{39–42}, whereas other evidence points to the fallopian tube^{43,44}. The first ovarian cancer model based

on transformation of the fallopian tube epithelium as the origin was derived by using the Müllerian-specific *Ovgp1* promoter to drive expression of the SV40 large T-antigen and thus induce tumorigenesis in the fallopian tube⁴⁵. More recently, Perets *et al.* generated a model in which they specifically deleted *BRCA*, *TP53*, or *PTEN* in the fallopian tube and found that these mice developed HGSCs, tubal transformation, and peritoneal spread⁴⁶. Interestingly, when the researchers removed the ovaries, the mice developed STIC lesions and tubal transformation but not peritoneal metastasis, suggesting that the ovary plays a crucial role in the spread of IP disease⁴⁶.

A second type of *in vivo* model is cell line-based xenografts, in which cancer cell lines are implanted into an immunocompromised mouse or, even better, into a mouse that is syngeneic with the cell line, such as the spontaneous ovarian cancer line ID8 derived from a C57Bl/6 mouse. Although this ID8 line has been used for many years, Walton *et al.* recently sequenced it and found that it was wild-type for *TP53* and *BRCA1* and *BRCA2*⁴⁷, whereas 98% of human ovarian cancers contain a *TP53* mutation. Introducing a *TP53* or *BRCA2* mutation (or both) caused these cells to develop tumors and surrounding microenvironment phenotype that more closely mimicked human ovarian cancers in terms of speed and distribution of metastases.

A third approach to translational mouse models is the use of patient-derived xenografts (PDXs), which are created by implanting patient specimens into mice to study tumor behaviors. Several groups have developed ovarian cancer PDXs^{48–51} that respond to treatment in a manner similar to that of the patients' tumors. For example, Landen *et al.* created subcutaneous PDX models of ovarian cancer and assessed gene expression in both the patients' tumors and the PDXs after they developed chemoresistance⁵⁰. The authors identified five affected signaling pathways (protein kinase A, GNRH, sphingosine-1-phosphate, α -adrenergic, and cholecystokinin/gastrin-mediated) that were shared between the patients' tumors and the corresponding PDXs. Models such as these provide usable platforms to study tumor and stromal elements contributing to tumorigenesis and the effects of various therapies.

Diagnosis and prevention

Screening in low-risk patients

No validated screening tests exist for early detection of ovarian cancer in low-risk women. Although some tests have been developed to assess known adnexal masses, the US Food and Drug Administration (FDA) recently issued a statement recommending against using any of these as screening tools in the general population⁵². Similarly, the US Preventative Services Task Force gives screening asymptomatic women a D grade, meaning that there is moderate to high certainty that the service has no net benefit or that the harms of such a service may outweigh any benefit⁵³. For example, the FDA has approved the OVA1 test for women who have already been found to have an ovarian tumor, but it is not a screening test. The largest randomized controlled trials (RCTs) have assessed a combination of serum markers and ultrasound imaging, but these tests have proved to have inadequate sensitivity or specificity, have resulted in high rates of unnecessary interventions (65–97% of

screen-positive women who underwent surgical intervention did not actually have cancer), or were unable to reduce ovarian cancer-related mortality^{54–56}. This is an important area for future research.

Special considerations in high-risk patients

Patients who carry particular inherited mutations warrant screening⁵⁷ because the lifetime risk of ovarian cancer in the general population is 1.3% but can be as high as 40–60% in *BRCA1* and *BRCA2* mutation carriers^{58–62} and 10–15% in Lynch syndrome mutation carriers⁶³. As additional high-risk mutations are identified in multi-gene panels, we may be able to identify more high-risk patients.

Advances in high-risk prevention

Women who carry high-risk mutations are recommended to undergo risk-reducing bilateral salpingo-oophorectomy (RRSO) (removal of the fallopian tubes and ovaries) by age 35 to 40 for *BRCA1* and 40 to 45 for *BRCA2*^{27,64}. A national trial (GOG-0199) comparing RRSO with longitudinal screening will hopefully clarify both the necessary screening frequency and the non-oncological outcomes of ovary removal, such as heart disease and osteoporosis⁶⁵, in high-risk patients.

Because removal of the ovary can cause earlier onset of menopause, increased risks to cardiac and bone health, and other impairments to quality of life, studies are underway to determine the efficacy of removing the fallopian tubes (salpingectomy) immediately but delaying ovary removal (oophorectomy) for several years. Harmsen *et al.* used previous data of cumulative ovarian cancer risk for *BRCA* mutation carriers to mathematically compare the risks of immediate RRSO with those of immediate salpingectomy with delayed oophorectomy⁶⁶. The authors concluded that a five-year delay in oophorectomy would increase the rates of ovarian cancer by 4.1% and 1.8% for those with mutations in *BRCA1* and *BRCA2*, respectively, even if the initial salpingectomy afforded no reduction of risk. Kwon *et al.* created a model to compare costs and benefits of RRSO at age 40 versus salpingectomy at age 40 with oophorectomy at age 50 in *BRCA1* and *BRCA2* mutation carriers⁶⁷. Although RRSO at age 40 was more effective in both cost and overall life expectancy, salpingectomy plus delayed oophorectomy resulted in higher quality-adjusted life expectancy.

Hormonal agents in high-risk patients

An important issue to consider is that RRSO is associated with menopausal symptoms such as sexual dysfunction, hypoactive sexual desire, and less frequent sexual encounters^{68–70}. Thus, RRSO patients may receive hormone therapy, which Kwon *et al.* assumed would not be the case in the cost–benefit analysis discussed above. Thus far, no RCTs have been conducted to address this issue. One recent systematic literature review⁷¹ assessed the safety of hormone therapy in RRSO patients with *BRCA* mutations and found that women were likely to benefit symptomatically from hormone therapy and did not have an increased risk of breast cancer, but there was insufficient evidence regarding ovarian cancer risk. Additional studies are needed to assess ovarian cancer risk and outcomes of risk-reducing procedures in patients carrying Lynch syndrome mutations.

Optimizing chemotherapy and developing innovative therapeutics

Optimizing chemotherapy

Chemotherapy has long been incorporated into the care of patients with HGSC; however, the how, when, and which have become less clear as more options are available for front-line treatment. In the first decade of the 21st century, two randomized trials (GOG 114 and GOG 172) demonstrated that, after optimal tumor resection, women who received combination intravenous/IP (IV/IP) cisplatin and paclitaxel-containing chemotherapy had significantly better progression-free survival (PFS) (5.7 and 5.5 months) and overall survival (OS) (11.0 and 15.9 months) than those who received IV-only regimens^{72,73}. This survival advantage in the IP groups was seen even though the IP patients had significant hematologic, metabolic, neurologic, and gastrointestinal toxicities, and only 71% and 42% of each study's IP participants completed all six cycles^{72,73}. Because of these toxicities and missed cycles, over time providers modified the regimen and instead gave patients alternate therapy schedules, reduced dosages, and substituted drugs, as described by Wright *et al.*⁷⁴. Another option for chemotherapy regimen was provided by a Japanese study showing that a lower but more frequent dose of paclitaxel (“dose-dense paclitaxel”) led to improved PFS and OS⁷⁵. Additionally, the GOG-0218 trial demonstrated that the use of bevacizumab in the front-line and maintenance setting improved PFS by 3.8 months when compared with conventional every-3-weeks carboplatin and paclitaxel⁷⁶.

Recently, the GOG-0252 trial was undertaken in an attempt to identify the best front-line regimen given the improved survival data seen with IP chemotherapy and dose-dense paclitaxel when compared with conventional every-3-weeks carboplatin and paclitaxel. This study had three arms, each of which included bevacizumab therapy in addition to (1) IV dose-dense paclitaxel and IV carboplatin, (2) IV dose-dense paclitaxel and IP carboplatin, and (3) IV/IP paclitaxel with IP cisplatin at a reduced dose. PFS and toxicities were found to be similar amongst all three treatment regimens, although some participant cross-over between arms may have clouded results⁷⁷. We are awaiting OS data as they mature to help determine whether there is a superior front-line regimen.

Not only has the best route been intensely debated but the optimal timing of therapy has been and is currently being studied. Chemotherapy is usually given either (1) only after primary debulking surgery (PDS) or (2) as both neoadjuvant chemotherapy (NACT) before and after interval debulking surgery (IDS). The goal of any cytoreductive surgery is to maximally reduce the disease, as doing so is well known to improve patient outcomes^{78–80}. However, recent trials have tried to determine whether patients receiving NACT and post-IDS chemotherapy have better outcomes than those receiving only chemotherapy after PDS. Initially, several large RCTs found that the NACT/IDS regimen was non-inferior to the PDS regimen in terms of PFS and OS and overall morbidities. However, the OS of the groups was lower than expected, suggesting that the included patients somehow differed from the larger collective population of patients with HGSC^{81–84}. Subsequent reports noted that recurrences after NACT/IDS

regimens were more likely to be platinum-resistant and were less responsive to second-line therapies than those that occurred after PDS regimens, and some studies even demonstrated better PFS and OS in those who received regimens after PDS^{85–90} when compared with those after NACT/IDS. There is likely a contributing biological factor, yet to be determined, for tumors that present as unresectable versus those that can be resected to no residual disease with PDS. Controversy with NACT/IDS exists given the possibility of a compromised responsiveness to additional lines of therapy including platinum-containing agents and possibly a risk of higher recurrence rates. Nonetheless, a NACT/IDS regimen may be the best option for patients with particular comorbidities, histological subtypes, or other clinical situations making them unable to tolerate an aggressive, up-front surgical procedure.

Developing innovative therapeutics

Traditionally, ovarian cancer has been treated with cytotoxic agent regimens chosen on the basis of cancer stage, and most patients have eventually developed chemotherapy resistance, leading to overwhelming disease burden and death. Researchers are working to find innovative methods to restore chemosensitivity and develop adjuvants to improve the function of cytotoxics to decrease required doses and improve toxicity profiles. In addition, researchers are investigating novel agents targeting specific tumor mutations. We highlight some promising findings below.

Preclinical development

Nanoparticle technology is a promising method by which to introduce therapeutics and minimize off-target effects. In one study, Landen *et al.* treated a mouse model of ovarian cancer with nanoliposomal particles containing small interfering RNAs targeting cancer stem cells in combination with either docetaxel or cisplatin⁹¹. This regimen reduced tumor growth more than chemotherapy alone. In another study, researchers used nanoliposomal particles to target a cell membrane transporter involved in cellular extrusion of chemotherapeutic drugs. This approach was able to restore paclitaxel sensitivity both *in vitro* and *in vivo*⁹². A nanoparticle derived of a naturally occurring alcohol was recently demonstrated to improve apoptosis and inhibit tumor growth when combined with paclitaxel *in vitro* and *in vivo*⁹³. Other promising therapeutics target various parts of the surrounding tumor stroma. For example, Wang *et al.* found that the peptide prosaposin could inhibit metastasis in a platinum-resistant PDX model by stimulating the release of anti-tumorigenic protein thrombospondin-1 from surrounding monocytes⁹⁴.

SHIVA and MATCH clinical trials

Given the success of targeted therapies based on tumor mutational status in lung cancer and melanoma, this approach is being investigated in other solid cancers, including ovarian cancer. The SHIVA (A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With

Refractory Cancer) trial in France was a multicenter, phase II RCT of 195 histology-agnostic, heavily pretreated patients (of whom 29 had ovarian cancer). Patients were randomly assigned to either the physician's choice of drug or a molecularly targeted agent that was matched to the patient tumor molecular profile but was not approved for that tumor type. Although the study reported no difference in PFS between the two groups⁹⁵, the study was powered to detect only a 15–30% improvement and may have missed smaller effects. In the ongoing National Cancer Institute-initiated Molecular Analysis for Therapy Choice (MATCH) trial, all recurrent, solid tumors undergo targeted exome sequencing to identify mutations, and the patients are treated with a matched targeted therapy until disease progression⁹⁶. This ongoing trial includes patients with ovarian cancer and will provide useful information about the value of this genomics-based approach to treatment.

FDA-approved agents

Only two targeted agents are currently FDA-approved for use in ovarian cancer. Olaparib, a poly-ribose polymerase (PARP) inhibitor, was approved in 2014 for use in patients with *BRCA1/2* mutations who have been treated with three or more previous lines of chemotherapy. Bevacizumab, a vascular endothelial growth factor (VEGF) anti-angiogenic, also received FDA approval in 2014 for use in recurrent, platinum-resistant patients in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin. A number of other targeted therapeutics, including additional PARP inhibitors, anti-angiogenics, tyrosine kinase inhibitors, and immunotherapeutics, are currently being investigated (Table 1).

Immunotherapy

The possible effectiveness of immunotherapeutic approaches in ovarian cancer was suggested by a 2003 study reporting that ovarian cancer patients whose tumors contained CD3⁺ T cells experienced a higher five-year OS rate than those whose tumors did not contain those cells (38% versus 4.5%). In another approach, patients are “immunized” with tumor antigens. Although positive antibody responses have been reported, no vaccination approach has yet improved any clinically relevant outcomes in ovarian cancer^{97–99}.

In several cancer types, investigators are attempting to block programmed death 1 (PD-1), a protein that protects tumor cells from immune system attack, but so far little work has been done in this area for ovarian cancer. In a single phase II study, the anti-PD-1 antibody nivolumab produced an overall response rate of 15% (3 out of 20) and a median PFS of 3.5 months. Similarly, in a preliminary report of a phase IB study using the anti-PD-1 antibody pembrolizumab in patients with ovarian cancer that expressed the PD-1 ligand, the overall response rate was 3 out of 20¹⁰⁰. Although the overall response rate was low, two patients had complete and durable remissions of up to one year.

Table 1. Recent and ongoing clinical trials using targeted therapeutics for high-grade serous Müllerian adenocarcinomas.

Class	Agent	Target(s)	Trial group/name, phase	Progression-free survival and overall survival, months
Anti-angiogenics				
	Bevacizumab ^a	VEGF	ICON-7, phase III ¹⁰¹ GOG-0218, phase III ⁷⁶	PFS 19.8/OS 36.6 PFS 11.2+14.1/OS 38.7+39.7
			OCEANS, phase III ¹⁰² AURELIAa, phase III ¹⁰³	PFS 12.4/OS 33.3 PFS 6.7/OS 16.6
	Cabozantinib	c-met, VEGFR2, RET, AXL	<i>NRG-GY001, phase II</i> ¹⁰⁴	-
	Cediranib	VEGFR2/3/4, c-kit	Multicenter, phase II ¹⁰⁵ <i>NRG-GY004, phase III</i> ¹⁰⁶ <i>NRG-GY005, phase II/III</i> ¹⁰⁷	PFS 5.2/OS 16.3 - -
	Fosbretabulin	Endothelial microtubules	GOG-0186I, phase II ¹⁰⁸	PFS 7.3/OS 24.6
	Trebananib/AMG386	Angiopoietin-1/2	TRINOVA1, phase III ^{109,110} <i>TRINOVA2-3, phase III</i> ^{111,112}	PFS 7.2/OS 19.3 -
PARP inhibitors				
	Olaparib ^a	PARP	Multicenter ^a , phase II ¹¹³ Multicenter, phase II ^{114,115} <i>NRG-GY004, phase III</i> ¹⁰⁶ <i>NRG-GY005, phase II/III</i> ¹⁰⁷	PFS 7.0/OS 16.6 PFS 8.4/OS 29.8 ^b - -
	Niraparib	PARP	ENGOT-OV16/Nova Trial (multi-arm), phase III ¹¹⁶ <i>QUADRA, phase II</i> ¹¹⁷	PFS 21+12.9+9.3 /OS not yet mature -
	Veliparib	PARP	<i>GOG-3005, phase III</i> ¹¹⁸	-
	Rucaparib	PARP	<i>ARIEL2-4, phase II/III</i> ¹¹⁹⁻¹²¹	-
	Pazopanib	PARP	<i>GOG-0186J, phase II</i> ¹²²	-
	Cabozantinib	PARP	<i>GOG-0186K, phase II</i> ¹²³	-
Immunologics				
	EGEN-001	IL-12	GOG-0170Q, phase II ¹²⁴	PFS 2.9/OS 9.2
	Nivolumab	PD-1	<i>NRG-GY003, phase II</i> ¹²⁵	-
	Ruxolitinib	JAK1, JAK2	<i>NRG-GY007, phase I/II</i> ¹²⁶	-
	VTX-2337	TLR8	<i>GOG-3003, phase II</i> ¹²⁷	-
Pathway inhibitors				
	Temsirolimus	MTOR	GOG-0268, phase II ¹²⁸	PFS 3.2/OS 11.6

^aUS Food and Drug Administration approval gained. ^bOverall survival (OS) may be underestimated; OS = 31.9 months when crossover poly-ribose polymerase (PARP) exposure post-trial is included¹²⁹. Italics indicate trial in progress or awaiting data analysis. GOG, Gynecologic Oncology Group; IL-12, interleukin-12; JAK, Janus Kinase; MTOR, mammalian target of rapamycin; NRG, NSABP/RTOG/GOG Collaborative Group; PD-1, programmed death 1; PFS, progression-free survival; TLR8, Toll-like receptor 8; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2.

Conclusions

Since the incorporation of taxane-containing chemotherapy into standard treatment, the survival of patients with ovarian cancer has improved only slightly. However, the current research highlighted here gives us hope that survival rates will continue to increase as there is further development of *in vivo* mouse models, *in vitro* tumor microenvironment models, identification of pathways activated in chemoresistance, immunotherapy, optimization of chemotherapy regimens, and development of targeted agents. In addition, cost models are needed to determine the

feasibility and sustainability of widespread usage of newly developed approaches.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References



1. Swerdlow M: Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. *Am J Obstet Gynecol.* 1959; **77**(1): 197–200.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. *CA Cancer J Clin.* 2016; **66**(1): 7–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
3. SEER Cancer Statistics Factsheets: Ovarian Cancer. National Cancer Institute. Bethesda, MD.
[Reference Source](#)
4. Di Saia PJ, Creasman WT: *Clinical Gynecologic Oncology*. 8th ed, ed. P.J.D. Saia, et al., Philadelphia, PA Elsevier/Saunders. 2012.
[Reference Source](#)
5. Aarnio M, Sankila R, Pukkala E, et al.: Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer.* 1999; **81**(2): 214–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Risch HA, McLaughlin JR, Cole DE, et al.: Prevalence and penetrance of germline *BRCA1* and *BRCA2* mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet.* 2001; **68**(3): 700–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Pal T, Permuth-Wey J, Betts JA, et al.: *BRCA1* and *BRCA2* mutations account for a large proportion of ovarian carcinoma cases. *Cancer.* 2005; **104**(12): 2807–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Finch A, Beiner M, Lubinski J, et al.: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a *BRCA1* or *BRCA2* Mutation. *JAMA.* 2006; **296**(2): 185–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Alvarez AA, Moore WF, Robboy SJ, et al.: K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary. *Gynecol Oncol.* 2001; **80**(2): 201–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Pearce CL, Templeman C, Rossing MA, et al.: Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol.* 2012; **13**(4): 385–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
11. Kurman RJ, Shih I: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. *Am J Surg Pathol.* 2010; **34**(3): 433–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
12. Dong A, Lu Y, Lu B: Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice. *J Cancer.* 2016; **7**(11): 1441–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Lee Y, Miron A, Drapkin R, et al.: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. *J Pathol.* 2007; **211**(1): 26–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Crum CP, Drapkin R, Miron A, et al.: The distal fallopian tube: a new model for pelvic serous carcinogenesis. *Curr Opin Obstet Gynecol.* 2007; **19**(1): 3–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Jarboe E, Folkins A, Nucci MR, et al.: Serous carcinogenesis in the fallopian tube: a descriptive classification. *Int J Gynecol Pathol.* 2008; **27**(1): 1–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Carlson JW, Miron A, Jarboe EA, et al.: Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. *J Clin Oncol.* 2008; **26**(25): 4160–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Eckert MA, Pan S, Hernandez KM, et al.: Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. *Cancer Discov.* 2016; **6**(12): 1342–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
18. McDaniel AS, Stall JN, Hovelson DH, et al.: Next-Generation Sequencing of Tubal Intraepithelial Carcinomas. *JAMA Oncol.* 2015; **1**(8): 1128–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
19. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. *Nature.* 2011; **474**(7353): 609–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
20. Vang R, Levine DA, Soslow RA, et al.: Molecular Alterations of *TP53* are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking *TP53* Mutations in The Cancer Genome Atlas Ovarian Study. *Int J Gynecol Pathol.* 2016; **35**(1): 48–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Norquist BM, Harrell MI, Brady MF, et al.: Inherited Mutations in Women With Ovarian Carcinoma. *JAMA Oncol.* 2016; **2**(4): 482–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
22. Loveday C, Turnbull C, Ramsay E, et al.: Germline mutations in *RAD51D* confer susceptibility to ovarian cancer. *Nat Genet.* 2011; **43**(9): 879–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Loveday C, Turnbull C, Ruark E, et al.: Germline *RAD51C* mutations confer susceptibility to ovarian cancer. *Nat Genet.* 2012; **44**(5): 475–6; author reply 476.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Meindl A, Hellebrand H, Wiek C, et al.: Germline mutations in breast and ovarian cancer pedigrees establish *RAD51C* as a human cancer susceptibility gene. *Nat Genet.* 2010; **42**(5): 410–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Ramus SJ, Song H, Dicks E, et al.: Germline Mutations in the *BRIP1*, *BARD1*, *PALB2*, and *NBN* Genes in Women With Ovarian Cancer. *J Natl Cancer Inst.* 2015; **107**(11): pii: djv214.
[PubMed Abstract](#) | [Free Full Text](#) | [F1000 Recommendation](#)
26. Walsh T, Casadei S, Lee MK, et al.: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A.* 2011; **108**(44): 18032–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
27. Genetic/Familial High-Risk Assessment: Breast and Ovarian V. 1.2017. *NCCN Clinical Practice Guidelines in Oncology.* 2016.
[Reference Source](#)
28. Patch A, Christie EL, Etemadmoghadam D, et al.: Whole-genome characterization of chemoresistant ovarian cancer. *Nature.* 2015; **521**(7553): 489–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
29. Pradeep S, Kim SW, Wu SY, et al.: Hematogenous metastasis of ovarian cancer: rethinking mode of spread. *Cancer Cell.* 2014; **26**(1): 77–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
30. Nieman KM, Kenny HA, Penicka CV, et al.: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med.* 2011; **17**(11): 1498–503.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
31. Hansen JM, Coleman RL, Sood AK: Targeting the tumour microenvironment in ovarian cancer. *Eur J Cancer.* 2016; **56**: 131–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Li H, Fan X, Houghton J: Tumor microenvironment: the role of the tumor stroma in cancer. *J Cell Biochem.* 2007; **101**(4): 805–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Kalluri R, Zeisberg M: Fibroblasts in cancer. *Nat Rev Cancer.* 2006; **6**(5): 392–401.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Lengyel E, Burdette JE, Kenny HA, et al.: Epithelial ovarian cancer experimental models. *Oncogene.* 2014; **33**(28): 3619–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. Davidowitz RA, Selfors LM, Iwanicki MP, et al.: Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. *J Clin Invest.* 2014; **124**(6): 2611–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Rankin EB, Fuh KC, Taylor TE, et al.: *AXL* is an essential factor and therapeutic target for metastatic ovarian cancer. *Cancer Res.* 2010; **70**(19): 7570–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Divine LM, Nguyen MR, Meller E, et al.: *AXL* modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. *Oncotarget.* 2016; **7**(47): 77291–77305.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Haemmerle M, Bottsford-Miller J, Pradeep S, et al.: *FAK* regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. *J Clin Invest.* 2016; **126**(5): 1885–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
39. Flesken-Nikitin A, Choi K, Eng JP, et al.: Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. *Cancer Res.* 2003; **63**(13): 3459–63.
[PubMed Abstract](#)
40. Dinulescu DM, Ince TA, Quade BJ, et al.: Role of *K-ras* and *Pten* in the development of mouse models of endometriosis and endometrioid ovarian cancer. *Nat Med.* 2005; **11**(1): 63–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
41. Wu R, Baker SJ, Hu TC, et al.: Type I to type II ovarian carcinoma progression: mutant *Trp53* or *Pik3ca* confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. *Am J Pathol.* 2013; **182**(4): 1391–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Wu R, Hu TC, Rehemtulla A, et al.: Preclinical testing of *PI3K/AKT/mTOR* signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. *Clin Cancer Res.* 2011; **17**(23): 7359–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Kim J, Coffey DM, Creighton CJ, et al.: High-grade serous ovarian cancer arises from fallopian tube in a mouse model. *Proc Natl Acad Sci U S A.* 2012; **109**(10): 3921–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Connolly DC, Bao R, Nikitin AY, et al.: Female mice chimeric for expression of the simian virus 40 *TAg* under control of the *MISIR* promoter develop epithelial ovarian cancer. *Cancer Res.* 2003; **63**(6): 1389–97.
[PubMed Abstract](#) | [F1000 Recommendation](#)
45. Sherman-Baust CA, Kuhn E, Valle BL, et al.: A genetically engineered

- ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. *J Pathol.* 2014; 233(3): 228–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
46. **F** Perets R, Wyant GA, Muto KW, *et al.*: Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in *BrcA*; *Tp53*; *Pten* models. *Cancer Cell.* 2013; 24(6): 751–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
47. **F** Walton J, Blagih J, Ennis D, *et al.*: CRISPR/Cas9-Mediated *Trp53* and *BrcA2* Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. *Cancer Res.* 2016; 76(20): 6118–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
48. **F** Topp MD, Hartley L, Cook M, *et al.*: Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. *Mol Oncol.* 2014; 8(3): 656–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
49. **F** Weroha SJ, Becker MA, Enderica-Gonzalez S, *et al.*: Tumorgrafts as *in vivo* surrogates for women with ovarian cancer. *Clin Cancer Res.* 2014; 20(5): 1288–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
50. **F** Dobbin ZC, Katre AA, Steg AD, *et al.*: Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. *Oncotarget.* 2014; 5(18): 8750–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
51. **F** Liu JF, Palakurthi S, Zeng Q, *et al.*: Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. *Clin Cancer Res.* 2016.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
52. Ovarian Cancer Screening Tests: Safety Communication - FDA Recommends Against Use. 2016.
[Reference Source](#)
53. Moyer VA, U.S. Preventive Services Task Force: Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med.* 2012; 157(12): 900–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Buys SS, Partridge E, Greene MH, *et al.*: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. *Am J Obstet Gynecol.* 2005; 193(5): 1630–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. **F** Jacobs IJ, Menon U, Ryan A, *et al.*: Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet.* 2016; 387(10022): 945–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
56. Kobayashi H, Yamada Y, Sado T, *et al.*: A randomized study of screening for ovarian cancer: a multicenter study in Japan. *Int J Gynecol Cancer.* 2008; 18(3): 414–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Rosenthal AN, Fraser L, Manchanda R, *et al.*: Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. *J Clin Oncol.* 2013; 31(1): 49–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in *BRCA1*-mutation carriers. Breast Cancer Linkage Consortium. *Am J Hum Genet.* 1995; 56(1): 265–71.
[PubMed Abstract](#) | [Free Full Text](#)
59. Brose MS, Rebbeck TR, Calzone KA, *et al.*: Cancer risk estimates for *BRCA1* mutation carriers identified in a risk evaluation program. *J Natl Cancer Inst.* 2002; 94(18): 1365–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Chen S, Parmigiani G: Meta-analysis of *BRCA1* and *BRCA2* penetrance. *J Clin Oncol.* 2007; 25(11): 1329–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Levy-Lahad E, Friedman E: Cancer risks among *BRCA1* and *BRCA2* mutation carriers. *Br J Cancer.* 2007; 96(1): 11–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Antoniou A, Pharoah PD, Narod S, *et al.*: Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet.* 2003; 72(5): 1117–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. **F** Møller P, Seppälä T, Bernstein I, *et al.*: Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut.* 2015; pii: gutjnl-2015-309675.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. Berek JS, Chalas E, Edelson M, *et al.*: Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. *Obstet Gynecol.* 2010; 116(3): 733–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Greene MH, Piedmonte M, Alberts D, *et al.*: A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. *Cancer Epidemiol Biomarkers Prev.* 2008; 17(3): 594–604.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. **F** Harmsen MG, Int'Hout J, Arts-de Jong M, *et al.*: Salpingectomy With Delayed Oophorectomy in *BRCA1/2* Mutation Carriers: Estimating Ovarian Cancer Risk. *Obstet Gynecol.* 2016; 127(6): 1054–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
67. **F** Kwon JS, Tinker A, Pansegrau G, *et al.*: Prophylactic salpingectomy and delayed oophorectomy as an alternative for *BRCA* mutation carriers. *Obstet Gynecol.* 2013; 121(1): 14–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
68. **F** Tucker PE, Bulsara MK, Salfinger SG, *et al.*: Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. *Gynecol Oncol.* 2016; 140(1): 95–100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
69. **F** Johansen N, Liavaag AH, Tanbo TG, *et al.*: Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. *Gynecol Oncol.* 2016; 140(1): 101–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
70. **F** Finch A, Metcalfe KA, Chiang JK, *et al.*: The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a *BRCA* mutation. *Gynecol Oncol.* 2011; 121(1): 163–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
71. **F** Birrer N, Chinchilla C, Del Carmen M, *et al.*: Is Hormone Replacement Therapy Safe in Women With a *BRCA* Mutation?: A Systematic Review of the Contemporary Literature. *Am J Clin Oncol.* 2016.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
72. Markman M, Bundy BN, Alberts DS, *et al.*: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *J Clin Oncol.* 2001; 19(4): 1001–7.
[PubMed Abstract](#)
73. **F** Armstrong DK, Bundy B, Wenzel L, *et al.*: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med.* 2006; 354(1): 34–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
74. Wright AA, Cronin A, Milne DE, *et al.*: Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. *J Clin Oncol.* 2015; 33(26): 2841–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. **F** Katsumata N, Yasuda M, Isonishi S, *et al.*: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. *Lancet Oncol.* 2013; 14(10): 1020–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
76. **F** Burger RA, Brady MF, Bookman MA, *et al.*: Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med.* 2011; 365(26): 2473–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
77. Walker JL, Brady MF, DiSilvestro PA, *et al.*: A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study. Society of Gynecologic Oncology 47th Annual Meeting. *J Clin Oncol.* 2016; 141(Supplement 1): 208.
[Publisher Full Text](#)
78. Bristow RE, Tomacruz RS, Armstrong DK, *et al.*: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol.* 2002; 20(5): 1248–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Aletti GD, Dowdy SC, Gostout BS, *et al.*: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. *Obstet Gynecol.* 2006; 107(1): 77–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Chang SJ, Hodeib M, Chang J, *et al.*: Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. *Gynecol Oncol.* 2013; 130(3): 493–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. **F** Vergote I, Tropé CG, Amant F, *et al.*: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med.* 2010; 363(10): 943–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
82. Kehoe S, Hook J, Nankivell M, *et al.*: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. *Lancet.* 2015; 386(9990): 249–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Fagotti A, Ferrandina G, Vizzielli G, *et al.*: Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. *Eur J Cancer.* 2016; 59: 22–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
84. Onda T, Satoh T, Saito T, *et al.*: Comparison of treatment invasiveness between

- upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. *Eur J Cancer*. 2016; 64: 22–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Bristow RE, Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. *Gynecol Oncol*. 2006; 103(3): 1070–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Chi DS, Musa F, Dao F, *et al.*: An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). *Gynecol Oncol*. 2012; 124(1): 10–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, *et al.*: Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. *Gynecol Oncol*. 2013; 129(1): 63–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Petrillo M, Ferrandina G, Fagotti A, *et al.*: Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. *Ann Surg Oncol*. 2013; 20(12): 3955–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. **F** da Costa AA, Valadares CV, Baiocchi G, *et al.*: Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. *Ann Surg Oncol*. 2015; 22(Suppl 3): S971–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
90. **F** Gadducci A, Cosio S, Zizioli V, *et al.*: Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. *Int J Gynecol Cancer*. 2017; 27(1): 28–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
91. Landen CN Jr, Goodman B, Katre AA, *et al.*: Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. *Mol Cancer Ther*. 2010; 9(12): 3186–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. **F** Zhang Y, Sriraman SK, Kenny HA, *et al.*: Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. *Mol Cancer Ther*. 2016; 15(10): 2282–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
93. **F** Han HD, Cho YJ, Cho SK, *et al.*: Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. *Mol Cancer Ther*. 2016; 15(4): 618–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
94. **F** Wang S, Blois A, El Rayes T, *et al.*: Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. *Sci Transl Med*. 2016; 8(329): 329ra34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
95. **F** Le Tourneau C, Delord JP, Gonçalves A, *et al.*: Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. *Lancet Oncol*. 2015; 16(13): 1324–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
96. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial. 2017.
[Reference Source](#)
97. Tse BW, Collins A, Oehler MK, *et al.*: Antibody-based immunotherapy for ovarian cancer: where are we at? *Ann Oncol*. 2014; 25(2): 322–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. Chester C, Dorigo O, Berek JS, *et al.*: Immunotherapeutic approaches to ovarian cancer treatment. *J Immunother Cancer*. 2015; 3: 7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. De Felice F, Marchetti C, Palaia I, *et al.*: Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. *J Immunol Res*. 2015; 2015: 191832.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Varga A, Piha-Paul SA, Ott PA, *et al.*: Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. ASCO Meeting Abstracts. 2015; 33(Suppl_15): 5510.
[Reference Source](#)
101. **F** Perren TJ, Swart AM, Pfisterer J, *et al.*: A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med*. 2011; 365(26): 2484–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
102. **F** Aghajanian C, Blank SV, Goff BA, *et al.*: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol*. 2012; 30(17): 2039–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
103. **F** Pujade-Lauraine E, Hilpert F, Weber B, *et al.*: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. *J Clin Oncol*. 2014; 32(13): 1302–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
104. Farley J: A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum. 2016.
[Reference Source](#)
105. Matulonis UA, Berlin S, Ivy P, *et al.*: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. *J Clin Oncol*. 2009; 27(33): 5601–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
106. Liu J: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. 2016.
[Reference Source](#)
107. Lee J: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS). 2016.
[Reference Source](#)
108. **F** Monk BJ, Sill MW, Walker JL, *et al.*: Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. *J Clin Oncol*. 2016; 34(19): 2279–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
109. Monk BJ, Poveda A, Vergote I, *et al.*: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol*. 2014; 15(8): 799–808.
[PubMed Abstract](#) | [Publisher Full Text](#)
110. **F** Monk BJ, Poveda A, Vergote I, *et al.*: Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. *Gynecol Oncol*. 2016; 143(1): 27–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
111. A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. 2016.
[Reference Source](#)
112. TRINOVA-3: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers. 2016.
[Reference Source](#)
113. Kaufman B, Shapira-Frommer R, Schmutzler RK, *et al.*: Olaparib monotherapy in patients with advanced cancer and a germline *BRCA1/2* mutation. *J Clin Oncol*. 2015; 33(3): 244–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
114. **F** Ledermann J, Harter P, Gourley C, *et al.*: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med*. 2012; 366(15): 1382–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
115. **F** Ledermann JA, Harter P, Gourley C, *et al.*: Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet Oncol*. 2016; 17(11): 1579–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
116. **F** Mirza MR, Monk BJ, Herrstedt J, *et al.*: Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. *N Engl J Med*. 2016; 375(22): 2154–2164.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
117. Clark R, Zaharoff B: A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA). 2016.
[Reference Source](#)
118. Bell-McGuinn KM SPS: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
[Reference Source](#)
119. A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2). 2016.
[Reference Source](#)
120. Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3). 2016.
[Reference Source](#)
121. ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients. 2016.
[Reference Source](#)
122. Richardson DL: A Randomized Phase IIB Evaluation of Weekly Paclitaxel

- plus Pazopanib versus Weekly Paclitaxel plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.** 2016.
[Reference Source](#)
123. Matulonis UA: **A Randomized Phase II Study of NCI Supplied Cabozantinib versus weekly paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.**
[Reference Source](#)
124. Alvarez RD, Sill MW, Davidson SA, *et al.*: **A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.** *Gynecol Oncol.* 2014; **133**(3): 433–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
125. Burger R: **Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer.** 2016.
[Reference Source](#)
126. Burger R: **A Phase III Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.** 2016.
[Reference Source](#)
127. Monk BJ: **Randomized Phase II Study of VTX-2337 in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in the treatment of recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.** 2016.
[Reference Source](#)
128. Behbakht K, Sill MW, Darcy KM, *et al.*: **Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.** *Gynecol Oncol.* 2011; **123**(1): 19–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
129. Matulonis UA, Harter P, Gourley C, *et al.*: **Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.** *Cancer.* 2016; **122**(12): 1844–52.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Referee Status:



Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- Ronny Drapkin**, Penn Ovarian Cancer Research Center, Department of Obstetrics & Gynecology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
Competing Interests: No competing interests were disclosed.
- Jonathan Berek**, Stanford Women's Cancer Center and Stanford Comprehensive Cancer Institute, Stanford University School of Medicine, California, USA
Competing Interests: No competing interests were disclosed.
- Steven Narod**, ^{1,2} ¹ Women's College Research Institute, Women's College Hospital, Toronto, Canada
² Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
Competing Interests: No competing interests were disclosed.